Chitosan Nanoparticles to Enhance the Inhibitory Effect of Natamycin on Candida albicans | Zendy

Yaling Liu | Zendy; Xiao-Ming Cui | Zendy; Liping Zhao | Zendy; Weifen Zhang | Zendy; ShouRong Zhu | Zendy; Jinlong Ma | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Chitosan Nanoparticles to Enhance the Inhibitory Effect of Natamycin on Candida albicans

Author(s) -

Yaling Liu,

Xiao-Ming Cui,

Liping Zhao,

Weifen Zhang,

ShouRong Zhu,

Jinlong Ma

Publication year - 2021

Publication title -

journal of nanomaterials

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.463

H-Index - 66

eISSN - 1687-4129

pISSN - 1687-4110

DOI - 10.1155/2021/6644567

Subject(s) - natamycin , chitosan , fungal keratitis , bioavailability , candida albicans , drug , antifungal , materials science , antifungal drug , microbiology and biotechnology , keratitis , pharmacology , chemistry , medicine , biology , dermatology , food science , organic chemistry

Fungal keratitis is a stubborn fungal infection that is widespread worldwide. It can even affect the health and life of a patient. At present, natamycin (NAT) is the first-line drug in the treatment of fungal keratitis, despite its disadvantages of clinical use, such as low drug bioavailability and poor water solubility. Herein, inspired by the adhesion properties of chitosan and its excellent drug loading and antifungal properties, we designed simple natamycin-chitosan nanoparticles (NAT-NPs) to investigate the feasibility of chitosan with NAT for eye treatment. Results showed that the NAT-NPs increased the antifungal effect of NAT due to the antifungal feature of chitosan NPs. Therefore, NAT-NPs are expected to become potential candidates for the treatment of fungal keratitis due to their high bacteriostasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research